Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update

Malignancy after solid organ transplantation remains a major cause of posttransplant mortality. The mammalian target of rapamycin (mTOR) inhibitor class of immunosuppressants exerts various antioncogenic effects, and the mTOR inhibitor everolimus is licensed for the treatment of several solid cancer...

Full description

Saved in:
Bibliographic Details
Published in:J Transplant
Main Authors: Holdaas, Hallvard, De Simone, Paolo, Zuckermann, Andreas
Format: Artigo
Language:Inglês
Published: Hindawi Publishing Corporation 2016
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078653/
https://ncbi.nlm.nih.gov/pubmed/27807479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/4369574
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items